EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudie

Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting

Esteban Daudén, Elena Escario, Luisa Martos-Cabrera iD, Susana Armesto, Enrique Herrera-Acosta, David Vidal, Eva Vilarrasa, Raquel Rivera, Pablo de la Cueva, Antonio Martorell, Ferran Ballesca, Isabel Belinchón iD und 12 weitere

International Journal of Dermatology · 2024-04 · 63 (4) · 503-511

DOI: 10.1111/ijd.16915 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Dermatology, online erschienen am 02.01.2024. Verfasst von Esteban Daudén und 23 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario de la Princesa. Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Psoriasis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biological therapy dose modification is a common practice in the long‐term treatment of plaque psoriasis.

Objective

The objective of the study was to determine prevalence, characteristics of patients, effectiveness, treatment survival of secukinumab dose reduction (SEC‐DR) strategy and assess its safety and cost implications.

Methods

A retrospective, observational, multicenter cohort study was conducted in patients with plaque psoriasis treated with secukinumab and up to 2 years of follow‐up.

Results

In 63/347 patients with an initial standard dose regimen, SEC‐DR was tried at any moment in 18.2% of them after sustained response. In 51 patients, the interval between administrations was increased while in 12 patients, monthly dose was reduced to 150 mg. Successful SEC‐DR was achieved in 77.8% of the patients, with sustained PASI response to the end of the study. Survival of secukinumab treatment and safety profile were not compromised by DR. The use of DR saved 33% of the cost, including failures in which standard treatment was resumed.

Limitations

The proper of the study designed and the arbitrary definition of “DR success.” Conclusion Off‐label SEC‐DR strategy was used in patients with sustained response to standard dose regimen; this strategy showed long‐term efficacy without compromising treatment survival or worsening the safety profile while also being cost saving.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedPsoriasisHumansCohort StudiesDrug TaperingRetrospective StudiesSeverity of Illness IndexTreatment Outcome

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, Humanizedsecukinumab

Autor:innen und Institutionen

  • Hospital Universitario de la Princesa. Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain.
  • Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Hospital Virgen de la Victoria, Málaga, Spain.
  • Hospital de Sant Joan Despí Moisés Broggi, Barcelona, Spain.
  • Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Hospital Universitario 12 de Octubre, Madrid, Spain.

ORCID-Profile: Luisa Martos-Cabrera, Isabel Belinchón, Josep Riera-Monroig

Zitieren

APA

Daudén, E., Escario, E., Martos-Cabrera, L., Armesto, S., Herrera-Acosta, E., Vidal, D., Vilarrasa, E., Rivera, R., de la Cueva, P., Martorell, A., Ballesca, F., Belinchón, I., Carretero, G., Rodríguez, L., Romero-Maté, A., Pujol-Montcusí, J., Salgado, L., Sahuquillo-Torralba, A., Coto-Segura, P., …, & Llamas-Velasco, M. (2024). Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting. International Journal of Dermatology, 63(4), 503-511. https://doi.org/10.1111/ijd.16915

Vancouver

Daudén E, Escario E, Martos-Cabrera L, Armesto S, Herrera-Acosta E, Vidal D, et al. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting. International Journal of Dermatology. 2024;63(4):503-511. doi:10.1111/ijd.16915

BibTeX
@article{Daudn2024,
  author = {Daudén, Esteban and Escario, Elena and Martos-Cabrera, Luisa and Armesto, Susana and Herrera-Acosta, Enrique and Vidal, David and Vilarrasa, Eva and Rivera, Raquel and de la Cueva, Pablo and Martorell, Antonio and Ballesca, Ferran and Belinchón, Isabel and Carretero, Gregorio and Rodríguez, Lourdes and Romero-Maté, Alberto and Pujol-Montcusí, J and Salgado, Laura and Sahuquillo-Torralba, Antonio and Coto-Segura, Pablo and Baniandrés, Ofelia and Feltes, R and Riera-Monroig, Josep and Garrido, Jesus and Llamas-Velasco, Mar},
  title = {Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting},
  journal = {International Journal of Dermatology},
  year = {2024},
  volume = {63},
  number = {4},
  pages = {503--511},
  doi = {10.1111/ijd.16915}
}
Kostenlos starten →